Nov. 29, 2012
-- Peptides International Inc., a privately held biotech company, announced today a change in its executive management. At a recent meeting of the Board of Directors of the Company, Dr. Bryce Johnson indicated that he will retire as CEO of the company at the end of the current year. After accepting Dr. Johnson’s decision, the Board appointed Dr. Michael Pennington, currently President and COO, to the position of President/CEO of the company. Dr. Pennington, who joined the company as Chief Technical Officer in 2010 was formerly President and COO of Bachem Bioscience in King of Prussia, Pennsylvania, and is an accomplished peptide chemist well-known within the industry.
In making the announcement Ms. Jackie Spatola, whose late husband Dr. Arno F. Spatola founded the company, stated, “We are genuinely grateful for the tremendous contributions that Dr. Johnson has made to Peptides International over the past seven years. Now, continuing forward with Dr. Pennington’s strong scientific background and guidance, PI is well poised for growth into the future.”
Ms. Spatola also noted that Dr. Johnson will remain a member of the Board and has been asked by the Board to serve as an advisor to executive management and to provide on-going consultant services as requested. Peptides International Inc. (PEPNET.COM) has its headquarters in Louisville, Kentucky, and specializes in manufacturing and distributing high purity biologically active peptides, enzyme substrates and inhibitors, innovative polymers and related products, and custom synthesis services to major corporations and research institutions throughout the world.